Progress in the study of age-related macular degeneration and lipid_Chinese Journal of Ocular Fundus Diseases

Authors：

Dong Jing ,  Zhang Lu

Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China;

Corresponding author：

Zhang Lu, Email: 13796089809@163.com

Keywords：

Macular degeneration/etiology; Lipids; Review

DOI：

10.3760/cma.j.cn511434-20190527-00186

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The etiology and pathogenesis of age-related macular degeneration (AMD) are unclear and difficult fot treatment. Some genetic research evidences in recent years have shown that the relationship between lipid metabolism-related gene polymorphism and AMD is statistically significant; it has also been found that blood lipid levels are related to AMD, and lipid-lowering drugs may have the effect of delaying the development of AMD in clinically. Abnormal lipid metabolism may play an important role in the occurrence and development of AMD. Clarifying the role of lipid metabolism in the occurrence and development of diseases will help reveal the pathogenesis of diseases and promote early diagnosis, monitoring and prevention of diseases, and provide an entry point for treatment.

Citation： Dong Jing, Zhang Lu. Progress in the study of age-related macular degeneration and lipid. Chinese Journal of Ocular Fundus Diseases, 2020, 36(10): 821-824. doi: 10.3760/cma.j.cn511434-20190527-00186 Copy

1.	Lim LS, itchell P, Seddon JM, et al. Age-related macular degeneration[J]. Lancet, 2012, 379(9827): 1728-1738. DOI: 10.1016/S0140-6736(12)60282-7.
2.	Wang L, Clark ME, Crossman DK, et al. Abundant lipid and protein components of drusen[J/OL]. PLoS One, 2010, 5(4): 10329[2010-04-23]. https://pubmed.ncbi.nlm.nih.gov/28560051/. DOI: 10.1371/journal.pone.0010329.
3.	Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration[J]. Lancet, 2018, 392(10153): 1147-1159. DOI: 10.1016/S0140-6736(18)31550-2.
4.	徐惠娟, 杨正林. 抗血管内皮生长因子药物治疗渗出型老年性黄斑变性的局限性研究现状[J]. 中华眼底病杂志, 2020, 36(2): 156-161. DOI: 10.3760/cma.j.issn.1005-1015.2020.02.017.Xu HJ, Yang ZL. Current research status of the limitations of anti-vascular endothelial growth factor drugs in the treatment of exudative age-related macular degeneration[J]. Chin J Ocul Fundus Dis, 2020, 36(2): 156-161. DOI: 10.3760/cma.j.issn.1005-1015.2020.02.017.
5.	Wang Y, Wang M, Zhang X, et al. The association between the lipids levels in blood and risk of age-related macular degeneration[J/OL]. Nutrients, 2016, 8(10): 663[2016-10-22]. https://pubmed.ncbi.nlm.nih.gov/28560051/. DOI: 10.3390/nu8100663.
6.	Colijn JM, Colijn J, den Hollander AI, et al. Increased high-density lipoprotein levels associated with age-related macular degeneration: evidence from the eye-risk and European eye epidemiology consortia[J]. Ophthalmology, 2019, 126(3): 393-406. DOI: 10.1016/j.ophtha.2018.09.045.
7.	Burgess S, Davey SG. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration[J]. Ophthalmology, 2017, 124(8): 1165-1174. DOI: 10.1016/j.ophtha.2017.03.042.
8.	Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in drusen formation and age related macular degeneration[J]. Exp Eye Res, 2001, 73(6): 887-896. DOI: 10.1006/exer.2001.1094.
9.	Eren E, Yilmaz N, Aydin O. High density lipoprotein and it's dysfunction[J]. Open Biochem J, 2012, 6: 78-93. DOI: 10.2174/1874091X01206010078.
10.	Rao VS, Kakkar VV. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response[J/OL]. Cholesterol, 2010, 2011: 274629[2010-11-25]. https://doi.org/10.1155/2011/274629. DOI:10.1155/2011/274629.
11.	Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein:association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis[J]. Arthritis Rheum, 2012, 64(6): 1828-1837. DOI: 10.1002/art.34363.
12.	Gordon SM, Deng J, Lu LJ, et al. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography[J]. J Proteome Res, 2010, 9(10): 5239-5249. DOI: 10.1021/pr100520x.
13.	Rezaee F, Casetta B, Levels JH, et al. Proteomic analysis of high-density lipoproteins[J]. Proteomic, 2006, 6(2): 721-730. DOI: 10.1002/pmic.200500191.
14.	Toomey CB, Kelly U, Saban DR, et al. Regulation of age-related macular degeneration-like pathology by complement factor H[J/OL]. Proc Natl Acad Sci USA, 2015, 112: 3040-3049[2015- 06-09]. https://pubmed.ncbi.nlm.nih.gov/25991857/. DOI: 10.1073/pnas.1424391112.
15.	Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants[J]. Nat Genet, 2016, 48(2): 134-143. DOI: 10.1038/ng.3448.
16.	Storti F, Raphael G, Griesser V, et al. Regulated efflux of photoreceptor outer segment- derived cholesterol by human RPE cells[J]. Exp Eye Res, 2017, 165: 65-77. DOI: 10.1016/j.exer.2017.09.008.
17.	Tserentsoodol N, Gordiyenko NV, Pascual I, et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors[J]. Mol Vis, 2006, 12: 1319-1333.
18.	Hasham SN, Pillarisetti S. Vascular lipases, inflammation and atherosclerosis[J]. Clin Chim Acta, 2006, 372(1-2): 179-183. DOI: 10.1016/j.cca.2006.04.020.
19.	Yu Y, Reynolds R, Fagerness J, et al. Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration[J]. Invest Ophthalmol Visl Sci, 2011, 52(7): 4663-4670. DOI: 10.1167/iovs.10-7070.
20.	Storti F, Klee K, Todorova V, et al. Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment epithelium (RPE) leads to retinal degeneration[J/OL]. Elife, 2019, 8: 45100[2019-03-13]. https://pubmed.ncbi.nlm.nih.gov/30864945/. DOI:10.7554/eLife.45100.
21.	Wang Y, Han Y, Zhang R, et al. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration[J/OL]. Sci Rep, 2015, 5: 15711[2015-10-27]. https://pubmed.ncbi.nlm.nih.gov/26503844/. DOI: 10.1038/srep15711.
22.	Chuo JY, Wiens M, Etminan M, et al. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies[J]. Ophthalmic Epidemiol, 2007, 14(6): 367-374. DOI: 10.1080/09286580701421684.
23.	Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration[J/OL]. PLoS One, 2013, 8(12): 83759[2013-12-31]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.1371/journal.pone.0083759.
24.	Vavvas DG, Daniels AB, Kapsala ZG, et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment[J]. EBioMedicine, 2016, 5: 198-203. DOI: 10.1016/j.ebiom.2016.01.033.
25.	Tian B, Al-Moujahed A, Bouzika P, et al. Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells[J/OL]. Sci Rep, 2017, 7(1): 2329[2017-05-24]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI:10.1038/s41598-017-02407-7.
26.	Martini E, Scorolli L, Burgagni MS, et al. Valutazione degli effetti retinici della somministrazione di simvastatina in pazienti affetti da degenerazione maculare senile[J]. Annali Di Ottalmologia e Clinica Oculistica, 1991, 117(11): 1121-1126.
27.	Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration[J/OL]. Cochrane Database Syst Rev, 2016(8): 006927[2016-08-04]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.1002/14651858.CD006927.pub5.
28.	Al-Holou SN, Tucker WR, Agrón E, et al. The association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9[J]. Ophthalmology, 2015, 122(12): 2490-2496. DOI: 10.1016/j.ophtha.2015.08.028.
29.	Maguire MG, Ying GS, McCannel CA, et al. Statin use and the incidence of advanced age-related macular degeneration in the complications of age-related macular degeneration prevention trial[J]. Ophthalmology, 2009, 116(12): 2381-2385. DOI: 10.1016/j.ophtha.2009.6.055.
30.	VanderBeek BL, Zacks DN, Talwar N, et al. Role of statins in the development and progression of age-related macular degeneration[J]. Retina, 2013, 33(2): 414-422. DOI: 10.1097/IAE.0b013e318276e0cf.
31.	Shalev V, Sror M, Goldshtein I, et al. Statin use and the risk of age related macular degeneration in a large health organization in Israel[J]. Ophthalmic Epidemiol, 2011, 18(2): 83-90. DOI: 10.3109/09286586.2011.560746.
32.	Roizenblatt M, Naranjit N, Maia M, et al. The question of a role for statins in age-related macular degeneration[J/OL]. Int J Mol Sci, 2018, 19(11): 3688[2018-11-21]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.3390/ijms19113688.
33.	Ma L, Wang Y, Du J, et al. The association between statin use and risk of age-related macular degeneration[J/OL]. Sci Rep, 2015, 5: 18280[2015-12-14]. https://www.nature.com/articles/srep18280. DOI: 10.1038/srep18280.

1. Lim LS, itchell P, Seddon JM, et al. Age-related macular degeneration[J]. Lancet, 2012, 379(9827): 1728-1738. DOI: 10.1016/S0140-6736(12)60282-7.
2. Wang L, Clark ME, Crossman DK, et al. Abundant lipid and protein components of drusen[J/OL]. PLoS One, 2010, 5(4): 10329[2010-04-23]. https://pubmed.ncbi.nlm.nih.gov/28560051/. DOI: 10.1371/journal.pone.0010329.
3. Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration[J]. Lancet, 2018, 392(10153): 1147-1159. DOI: 10.1016/S0140-6736(18)31550-2.
4. 徐惠娟, 杨正林. 抗血管内皮生长因子药物治疗渗出型老年性黄斑变性的局限性研究现状[J]. 中华眼底病杂志, 2020, 36(2): 156-161. DOI: 10.3760/cma.j.issn.1005-1015.2020.02.017.Xu HJ, Yang ZL. Current research status of the limitations of anti-vascular endothelial growth factor drugs in the treatment of exudative age-related macular degeneration[J]. Chin J Ocul Fundus Dis, 2020, 36(2): 156-161. DOI: 10.3760/cma.j.issn.1005-1015.2020.02.017.
5. Wang Y, Wang M, Zhang X, et al. The association between the lipids levels in blood and risk of age-related macular degeneration[J/OL]. Nutrients, 2016, 8(10): 663[2016-10-22]. https://pubmed.ncbi.nlm.nih.gov/28560051/. DOI: 10.3390/nu8100663.
6. Colijn JM, Colijn J, den Hollander AI, et al. Increased high-density lipoprotein levels associated with age-related macular degeneration: evidence from the eye-risk and European eye epidemiology consortia[J]. Ophthalmology, 2019, 126(3): 393-406. DOI: 10.1016/j.ophtha.2018.09.045.
7. Burgess S, Davey SG. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration[J]. Ophthalmology, 2017, 124(8): 1165-1174. DOI: 10.1016/j.ophtha.2017.03.042.
8. Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in drusen formation and age related macular degeneration[J]. Exp Eye Res, 2001, 73(6): 887-896. DOI: 10.1006/exer.2001.1094.
9. Eren E, Yilmaz N, Aydin O. High density lipoprotein and it's dysfunction[J]. Open Biochem J, 2012, 6: 78-93. DOI: 10.2174/1874091X01206010078.
10. Rao VS, Kakkar VV. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response[J/OL]. Cholesterol, 2010, 2011: 274629[2010-11-25]. https://doi.org/10.1155/2011/274629. DOI:10.1155/2011/274629.
11. Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein:association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis[J]. Arthritis Rheum, 2012, 64(6): 1828-1837. DOI: 10.1002/art.34363.
12. Gordon SM, Deng J, Lu LJ, et al. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography[J]. J Proteome Res, 2010, 9(10): 5239-5249. DOI: 10.1021/pr100520x.
13. Rezaee F, Casetta B, Levels JH, et al. Proteomic analysis of high-density lipoproteins[J]. Proteomic, 2006, 6(2): 721-730. DOI: 10.1002/pmic.200500191.
14. Toomey CB, Kelly U, Saban DR, et al. Regulation of age-related macular degeneration-like pathology by complement factor H[J/OL]. Proc Natl Acad Sci USA, 2015, 112: 3040-3049[2015- 06-09]. https://pubmed.ncbi.nlm.nih.gov/25991857/. DOI: 10.1073/pnas.1424391112.
15. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants[J]. Nat Genet, 2016, 48(2): 134-143. DOI: 10.1038/ng.3448.
16. Storti F, Raphael G, Griesser V, et al. Regulated efflux of photoreceptor outer segment- derived cholesterol by human RPE cells[J]. Exp Eye Res, 2017, 165: 65-77. DOI: 10.1016/j.exer.2017.09.008.
17. Tserentsoodol N, Gordiyenko NV, Pascual I, et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors[J]. Mol Vis, 2006, 12: 1319-1333.
18. Hasham SN, Pillarisetti S. Vascular lipases, inflammation and atherosclerosis[J]. Clin Chim Acta, 2006, 372(1-2): 179-183. DOI: 10.1016/j.cca.2006.04.020.
19. Yu Y, Reynolds R, Fagerness J, et al. Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration[J]. Invest Ophthalmol Visl Sci, 2011, 52(7): 4663-4670. DOI: 10.1167/iovs.10-7070.
20. Storti F, Klee K, Todorova V, et al. Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment epithelium (RPE) leads to retinal degeneration[J/OL]. Elife, 2019, 8: 45100[2019-03-13]. https://pubmed.ncbi.nlm.nih.gov/30864945/. DOI:10.7554/eLife.45100.
21. Wang Y, Han Y, Zhang R, et al. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration[J/OL]. Sci Rep, 2015, 5: 15711[2015-10-27]. https://pubmed.ncbi.nlm.nih.gov/26503844/. DOI: 10.1038/srep15711.
22. Chuo JY, Wiens M, Etminan M, et al. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies[J]. Ophthalmic Epidemiol, 2007, 14(6): 367-374. DOI: 10.1080/09286580701421684.
23. Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration[J/OL]. PLoS One, 2013, 8(12): 83759[2013-12-31]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.1371/journal.pone.0083759.
24. Vavvas DG, Daniels AB, Kapsala ZG, et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment[J]. EBioMedicine, 2016, 5: 198-203. DOI: 10.1016/j.ebiom.2016.01.033.
25. Tian B, Al-Moujahed A, Bouzika P, et al. Atorvastatin promotes phagocytosis and attenuates pro-inflammatory response in human retinal pigment epithelial cells[J/OL]. Sci Rep, 2017, 7(1): 2329[2017-05-24]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI:10.1038/s41598-017-02407-7.
26. Martini E, Scorolli L, Burgagni MS, et al. Valutazione degli effetti retinici della somministrazione di simvastatina in pazienti affetti da degenerazione maculare senile[J]. Annali Di Ottalmologia e Clinica Oculistica, 1991, 117(11): 1121-1126.
27. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration[J/OL]. Cochrane Database Syst Rev, 2016(8): 006927[2016-08-04]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.1002/14651858.CD006927.pub5.
28. Al-Holou SN, Tucker WR, Agrón E, et al. The association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9[J]. Ophthalmology, 2015, 122(12): 2490-2496. DOI: 10.1016/j.ophtha.2015.08.028.
29. Maguire MG, Ying GS, McCannel CA, et al. Statin use and the incidence of advanced age-related macular degeneration in the complications of age-related macular degeneration prevention trial[J]. Ophthalmology, 2009, 116(12): 2381-2385. DOI: 10.1016/j.ophtha.2009.6.055.
30. VanderBeek BL, Zacks DN, Talwar N, et al. Role of statins in the development and progression of age-related macular degeneration[J]. Retina, 2013, 33(2): 414-422. DOI: 10.1097/IAE.0b013e318276e0cf.
31. Shalev V, Sror M, Goldshtein I, et al. Statin use and the risk of age related macular degeneration in a large health organization in Israel[J]. Ophthalmic Epidemiol, 2011, 18(2): 83-90. DOI: 10.3109/09286586.2011.560746.
32. Roizenblatt M, Naranjit N, Maia M, et al. The question of a role for statins in age-related macular degeneration[J/OL]. Int J Mol Sci, 2018, 19(11): 3688[2018-11-21]. https://pubmed.ncbi.nlm.nih.gov/24391822/. DOI: 10.3390/ijms19113688.
33. Ma L, Wang Y, Du J, et al. The association between statin use and risk of age-related macular degeneration[J/OL]. Sci Rep, 2015, 5: 18280[2015-12-14]. https://www.nature.com/articles/srep18280. DOI: 10.1038/srep18280.

Chinese Journal of Ocular Fundus Diseases

Progress in the study of age-related macular degeneration and lipid

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content